A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity

NCT07508241 · tracked via the Priya Life Science USA tracker

Sponsor

Pfizer

Phase

Phase 1

Started

2026-03-31

Last updated

2026-07-09

Condition(s) studied

ObesityOverweight and/or ObesityOverweightDrug Interaction

Investigational drug(s) / intervention(s)

PF-08653944Acetaminophen

PF-08653944: Subcutaneous Injection

Acetaminophen: Oral suspension

Study summary

This study looks at how a study medicine called PF-08653944 affects how quickly the stomach empties food after eating. It is being done in adults who are overweight or have obesity.

Participants will receive the study medicine for a short period, and doctors will measure how the medicine moves through the stomach and monitor safety. The goal is to better understand how this medicine works in the body and to check for any side effects.

The information from this study may help researchers plan future studies of this medicine.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: * Adults ≥18 years at screening, male or female, generally healthy as determined by medical history, physical examination, laboratory tests, and ECG. * Body mass index (BMI) 27-45 kg/m² and body weight \>50 kg (110 lb). * Participants with overweight or obesity Exclusion Criteria: * History or presence of clinically significant medical conditions, including but not limited to: --Cardiovascular, hepatic, renal, pulmonary, endocrine, hematologic, neurologic, gastrointestinal (including pancreatitis or gallbladder disease), or significant psychiatric disorders. * Any form of diabetes, HbA1c ≥6.5%, or fasting plasma glucose ≥126 mg/dL. * Prior exposure to a GLP-1 receptor agonist within 90 days before first dose, or prior participation in a study with PF-08653944.

Primary outcome measure(s)

Acetaminophen Pharmacokinetic (PK) Parameters: Maximum observed plasma concentration (Cmax) — Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.
To assess the effect of multiple SC doses of PF-08653944 on the plasma PK profile of acetaminophen, a marker for gastric emptying, in healthy adult participants with overweight or obesity.
Acetaminophen PK parameters: Area under the plasma concentration (AUC) — Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.
To assess the effect of multiple SC doses of PF-08653944 on the plasma PK profile of acetaminophen, a marker for gastric emptying, in healthy adult participants with overweight or obesity.
Acetaminophen PK parameters: Time to Maximum concentration (Tmax) — Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.

Trial sites (1)

Facility	City	Region	Status
Pfizer Clinical Research Unit - New Haven	New Haven	Connecticut

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07508241 on ClinicalTrials.gov ↗ ← All trials in the USA